This study aims to evaluate clinicopathological features and prognostic outcomes associated with expression of key components of the uPA system in primary resected esophageal, gastro-oesophageal junction and gastric adenocarcinomas. Although the uPA system is a proven biomarker in various solid tumors, its significance in gastro-oesophageal cancer has not been established. Julia Yu Jia Chen 1,2, Daniel Brungs 3,4,5,6, Morteza Aghmesheh 3,5,6, Kara Perrow 3,4,6, Therese Becker 6,7,8,9, Martin Carolan 3,5,6, Marie Ranson 3,4,6ġCancer Care Centre, St George Hospital, Kogarah, New South Wales, AustraliaĢSt George Clinical School, University of New South Wales, Kogarah, New South Wales, AustraliaģIllawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, AustraliaĤSchool of Biological Sciences, University of Wollongong, Wollongong, New South Wales, AustraliaĥIllawarra Cancer Centre, Wollongong Hospital, Wollongong, New South Wales, AustraliaĦCONCERT, Translational Cancer Research Centre, Sydney, New South Wales, AustraliaħIngham Institute of Applied Medical Research, Liverpool Hospital, Liverpool, New South Wales, AustraliaĨSchool of Medicine, University of Western Sydney, Liverpool, New South Wales, AustraliaĩSouth Western Medical School, University of New South Wales, Liverpool, New South Wales, AustraliaĪim: The urokinase plasminogen activation (uPA) system is a key pathway in facilitating tumor invasion and establishment of metastases. 181 EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATION SYSTEM IN PRIMARY GASTRO-ESOPHAGEAL ADENOCARCINOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS CTCs can provide real-time snapshots of HER2 status for tumor monitoring that may help informed treatment decisions. Interestingly, in time point cases, we observed changing HER2 profiles in the CTCs of patients as the tumor progresses during the course of treatment.Ĭonclusion: There is a strong concordance of HER2 status in CTCs and primary tumor.
Worse progression-free survival is observed in patients with five or more CTCs per 7.5 mL of blood, suggesting significant prognostic relevance of HER2 overexpression in CTCs. Concordance rate of HER2 positivity between CTCs and tumor tissue is 82.4% (14 out of 17 patients), while the concordance rate of HER2 negativity is 100% between CTCs and tumor tissues (nine out nine). Both HER2 amplification and chromosome 17 polysomy can be detected using FISH in the CTC samples. Results: The number of CTCs ranges between 0 and 30 per 7.5 mL of blood. Conventional immunohistochemistry (IHC) of tumor tissues was done to evaluate the HER2 status of the primary tumor.
Fluorescence in situ hybridization (FISH) of circulating tumor cells was performed. Methods: The CTCs were isolated from peripheral blood samples using ClearCell FX, a label-free spiral microfluidics-based system. In our study, we analyzed the HER2 status of 26 advanced stage breast cancer patient samples in the Asian population in the tumor tissue and CTCs. While tissue sampling is invasive, liquid biopsy approach using circulating tumor cells (CTCs) provides accessible tumor material to phenotype the HER2 status of the patient to guide treatment decisions. 180 REAL-TIME HER2 STATUS MONITORING USING CIRCULATING TUMOR CELLSĪli Asgar Bhagat 1, Man Chun Leong 1, Tse Hui Lim 2, Yong Wei Chua 2, Garima Singh 1, Andrew Wu 1, Yifang Lee 1, Alvin Soon-Tiong Lim 2, Tony Kiat Hon Lim 2, Darren Wan-Teck Lim 3, Yoon-Sim Yap 4ġClearbridge Biomedics Pte Ltd, Singapore, SingaporeĢDepartment of Pathology, Singapore General Hospital, SingaporeĪims: HER2 status can alter during the course of breast tumor development.
0 kommentar(er)
